Pfizer Ltd. — Regulatory Filings 2026

Apr 24, 2026

Pfizer

Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel: +91 22 6693 2000 Fax: +91 22 2654 0274

April 24, 2026

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs / Madam,

Sub: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has received an Assessment Order on April 23, 2026 issued by Income-tax Department – Assessment Unit, under section 143(3) read with sections 144C(3) & 144B of the Income Tax Act, 1961, basis the scrutiny of returns for the Financial Year 2022-23, for a tax demand of Rs. 85,73,96,440/- (Rupees Eighty Five Crore Seventy Three Lakhs Ninety Six Thousand Four Hundred Forty only). The Income-tax Department – Assessment Unit has also issued a show cause notice for initiating penalty proceedings under section 274 read with section 270A of the Income-tax Act,1961 in respect of the above assessment.

The Company is in the process of evaluating the said Order and will take appropriate steps, including filing of appeal and/or application for stay, within the prescribed timelines. Based on a preliminary factual and legal assessment, the Company believes that it has strong grounds on merits. The Company does not expect the said Order to have any material impact on its financial position, operations or other activities at this stage.

The additional details required to be disclosed pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as Annexure A.

Request you to please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair
Digitally signed by Prajeet Nair
Date: 2026.04.24 13:31:30
+05'30'

Prajeet Nair
Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311
Email ID: contactus.india@pfizer.com
Website: www.pfizerltd.co.in

---

Annexure A

Additional information pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Details
1	Name of Authority	Income-tax Department – Assessment Unit
2	Nature and details of the action(s) taken or order(s) passed	The Assessment Order received under section 143(3) read with sections 144C(3) & 144B of the Income Tax Act, 1961 for a Tax demand of Rs. 85,73,96,440/- (Rupees Eighty Five Crore Seventy Three Lakh Ninety-Six Thousand Four Hundred Forty Only)

The Company has also received a show cause notice for initiating penalty proceedings under section 274 read with section 270A of the Income-tax Act,1961. |
| 3 | Date of receipt of direction or order | April 23, 2026 |
| 4 | Details of the violation(s) / contravention(s) committed or alleged to be committed | Income-tax Department – Assessment Unit has raised the demand stating alleged under reporting of income on account of disallowance of expenses in the Income Tax return filed for the financial year 2022-23. |
| 5 | Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible | The Company is in the process of evaluating the Order and will take appropriate steps, including filing of appeal and/or application for stay, within the prescribed timelines.

Based on a preliminary factual and legal assessment, the Company believes that it has strong grounds on merits. The Company does not expect the said Order to have any material impact on its financial position, operations or other activities at this stage. |